Figure 5

Rosiglitazone alone does not affect MerTK expression, whereas T0901317 upregulates MerTK regardless of M2c polarization. Healthy monocytes were cultured in serum-free medium with or without the PPAR-γ agonist rosiglitazone (0.1-10 μM) (A-B) or the LXR agonist T0901317 (0.001-1 μM) (C-D), for 4 days. Expression of MerTK (n = 5 for either PPAR-γ or LXR stimulation assays), CD163 (n = 4) and CD16 (n = 3) was measured by flow cytometry. (B and D) Pooled data are represented as mean values ± SEM. Analysis was performed using one-way repeated measures ANOVA with Newman-Keuls multiple comparisons test and Student’s paired t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Each set of data is representative of three to five independent experiments.